Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

nt to the end of the quarter, Omeros received a payment of $12.5 million from CCIC pursuant to the terms of the settlement agreement. Omeros also received $4.9 million in net proceeds from the sale of 373,700 shares of its common stock, sold at an average price of $13.29 per share, pursuant to the company's at-the-market equity facility in October 2013.

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for the second half of 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-l
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... INCLINE VILLAGE, Nev. , March 4, 2015 PDL ... that the adjusted conversion rate for the: , ... Notes), is 174.8506 shares of common stock per $1,000 principal ... The conversion rate for the note is adjusted ... be paid on March 12, 2015, to all stockholders who own ...
(Date:3/4/2015)... 4, 2015 In an article published and ... for Health Security review the clinical aspects of diseases ... as bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related ... website of the New England Journal of Medicine ... Toner , and Tom Inglesby—review the clinical management of ...
(Date:3/4/2015)... BALTIMORE , March 4, 2015 The ... of its 2015 Fellows in the Emerging Leaders in ... fostering future leaders in the field of biosecurity, UPMC ... biosecurity from a wide array of backgrounds, including biological ... private sector. "With the vision and ...
(Date:3/4/2015)... March 4, 2015  Brooklyn residents now have a ... chronic pain and injuries. Nunzio Saulle , M.D., ... opening of his NJS Physical Medicine and Rehabilitation (PM&R) ... Thursday, March 5, 2015. Health Plus Management, LLC is ... located at 1178 Flatbush Avenue. This new PM&R practice ...
Breaking Biology Technology:PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2Latest Clinical Information On Bioterrorism Threats 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... Company to Make Key Marketing Claims, HARBIN, ... Inc. (the "Company") (OTC Bulletin Board: CKGT), a,vertically ... of cactus-based consumer products in China, announced today ... the Company,s Cactus,Cattle Feed. The studies, which included ...
... after an individual becomes infected with HIV the virus ... central nervous system [CNS]). Although this causes no immediate ... dementia and encephalitis (acute inflammation of the brain that ... HIV (SIV) also sometimes develop CNS damage and provide ...
... SAN FRANCISCO, Calif., June 3 Sunesis,Pharmaceuticals, Inc. ... of its,late-stage development leadership team with the appointment ... Vice President, Research and,Development and Mary G. Bolton, ... Judith A. Fox, Ph.D., has been promoted to ...
Cached Biology Technology:China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Company's Cactus Cattle Feed 2China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Company's Cactus Cattle Feed 3Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 2Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 3Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 4Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 5Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595) 6
(Date:3/4/2015)... , Mar. 04, 2015 Research and ... the addition of the "Global Biometrics Market ... offering. The market for biometric authentication ... of around 14% till 2020 The ... be increasing security needs, government projects and constant ...
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:3/2/2015)... 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced a new implementation of its ... rapid and secure transactions and reliable identification for ... a turnkey solution providing mouse and keyboard peripheral ... fingerprint ID solutions into their product offerings, bringing ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... won the "Most Creative Visualization" award in the "commercial" ... achievement we are extremely proud of. iDEA is Illumina,s ... new and creative visualization and data analysis techniques. ... very first moment we heard about it. Genomatix is ...
... Kan. -- Preliminary research at Kansas State University may make ... scientists believe that cellulose, the most common organic compound on ... biofuels -- if a procedure to effectively break it down ... gives plants their rigidity. Kathrin Schrick, assistant professor in ...
... This press release is available in Spanish ... waters of the European Atlantic Ocean and, nevertheless, resists stock ... the mistakes made by humans. Ms Nerea Goikoetxea, a researcher ... the population dynamics of the northern European hake population, observing ...
Cached Biology News:Learning secrets of world's most common organic compound driving research for biofuels 2Hake population has withstood overfishing, thanks to the warming of the sea 2Hake population has withstood overfishing, thanks to the warming of the sea 3
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
...
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Request Info...
Biology Products: